Suven Life secures Process Patents in Europe, Japan and New Zealand
Suven Life Sciences Ltd (Suven) announces today that the grant of of one (1) process patent from Europe (3077375), one (1) process patent from Japan (6151453) and one (1) process patent from New Zealand (719671) corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.
These process patents are for our pipeline compounds which are in the class of selective 5-HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
About Suven Life Sciences
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.
In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.
For more information please visit our Web site at http://www.suven.com